Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CEO Sells 40,992 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the transaction, the chief executive officer now directly owns 1,283,362 shares of the company’s stock, valued at $4,209,427.36. The trade was a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Neuronetics Stock Performance

Shares of STIM stock opened at $3.97 on Thursday. The company’s fifty day simple moving average is $2.09 and its two-hundred day simple moving average is $1.38. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.07.

Institutional Investors Weigh In On Neuronetics

A number of hedge funds have recently made changes to their positions in STIM. Geode Capital Management LLC grew its holdings in Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after buying an additional 8,466 shares in the last quarter. David J Yvars Group boosted its position in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the last quarter. Tradewinds LLC. purchased a new position in shares of Neuronetics in the fourth quarter valued at $32,000. GSA Capital Partners LLP raised its stake in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after purchasing an additional 30,837 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after purchasing an additional 54,442 shares during the last quarter. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.